αβ-T-cell-depleted haploidentical hematopoietic stem cell transplantation in children with chemorefractory acute myeloid leukemia
Authors:
- L. N. ShelikhovaLSL. N. Shelikhova
- M. A. IlushinaMIM. A. Ilushina
- K. V. SemiglazovaKSK. V. Semiglazova
- Zh. B. ShekhovtsovaZSZh. B. Shekhovtsova
- D. A. ShashelevaDSD. A. Shasheleva
- R. D. KhismatullinaRKR. D. Khismatullina
- E. E. KurnikovaEKE. E. Kurnikova
- D. N. BalashovDBD. N. Balashov
- S. A. RadyginaSRS. A. Radygina
- P. E. TrakhtmanPTP. E. Trakhtman
- I. I. KalininaIKI. I. Kalinina
Open Access
- 28 June 2019
- journal article
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (2) , 11-21
Abstract
Primary refractory and relapsed refractory acute myeloid leukemia remains an unresolved problem in pediatric oncology. Children with AML who fail to achieve complete remission on high-dose cytarabine and antracyclines have no chance for survival without allogeneic hematopoietic stem cell transplantation. We evaluated the outcome of αβ-T-cell-depleted haploidentical transplantation in a cohort of children with chemorefractory acute myeloid leukemia. Thirty-six patients with either primary refractory (n = 14) or relapsed refractory (n = 22) acute myeloid leukemia in active disease status received a transplantation from haploidentical donors. The preparative regimen included cytoreduction with fludarabine and cytarabine and subsequent treatment with treosulfan and either melphalan or thiophosphamide. Serotherapy consisted of antithymocyte globuline in 14 pts and targeted immunomodulation with tocilizumab +/- abatacept in 22 pts. Grafts were PBSCs engineered by TCR-αβ/CD19 depletion. Posttransplant preemptive therapy included modified donor lymphocyte infusions with or without hypomethylating agents. Complete remission was achieved in 30 (83%) рts. The cumulative incidence of acute GVHD grade II–IV was 25%, and the cumulative incidence of chronic GVHD was 18%. Transplant-related mortality was 6%, and relapse incidence was 48%. Event-free survival was 46%, and overall survival was 41% at 2 years. Good early recovery of NK cells was associated with significantly improved survival and decreased relapse incidence. Our data suggest that αβ-T-cell-depleted haploidentical HSCT provides a reasonable chance of cure in a cohort of children with chemorefractory acute myeloid leukemia and creates a solid basis for further improvement. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology.Keywords
This publication has 23 references indexed in Scilit:
- Comparison of two cytoreductive regimens for αβ‐T‐cell‐depleted haploidentical HSCT in pediatric malignancies: Improved engraftment and outcome with TBI‐based regimenPediatric Blood & Cancer, 2017
- Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletionBlood, 2017
- Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experienceBone Marrow Transplantation, 2017
- TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemiaBone Marrow Transplantation, 2016
- Single-Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with TCRαβ and CD19 Depletion in Children with Primary Immunodeficiency SyndromesTransplantation and Cellular Therapy, 2015
- Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patientsBone Marrow Transplantation, 2015
- HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disordersBlood, 2014
- Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panelBlood, 2012
- Unrelated Donor Bone Marrow Transplantation for Children With Acute Myeloid Leukemia Beyond First Remission or Refractory to ChemotherapyJournal of Clinical Oncology, 2008
- High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remissionBone Marrow Transplantation, 2008